Personalis and Tempus Expand Collaboration to Biopharma
2024年12月16日 - 10:00PM
ビジネスワイヤ(英語)
Expanded collaboration to yield greater
biopharma access to Personalis’ MRD solution
Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq:
TEM) announced today that the companies have expanded their
commercial relationship. The companies agreed in November 2023 to
collaborate and bring ultra-sensitive MRD testing to market and
launched their efforts at the 2024 American Society of Clinical
Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive
commercial diagnostic partner for Personalis’ ultra-sensitive
tumor-informed MRD product, NeXT Personal® Dx, for broad patient
adoption in breast and lung cancers, and for immunotherapy
monitoring across all solid tumors.
Following a positive reaction from the diagnostic market, the
companies have agreed to expand their relationship to the biopharma
industry. Under this expanded relationship, Tempus will be enabled
to offer Personalis’ NeXT Personal MRD product to pharmaceutical
and biotech customers who wish to bundle MRD testing with other
Tempus offerings in a given study.
“While we already offer NeXT Personal through our own biopharma
channel, we are pleased to leverage Tempus’ integrated platform as
well for these biopharma customers who desire to combine NeXT
Personal with other Tempus products,” said Chris Hall, CEO of
Personalis. “We believe the expansion of the relationship with
Tempus will accelerate market penetration of our leading
ultra-sensitive MRD platform and allow us to better capitalize on
the opportunity.”
About Personalis, Inc.
At Personalis, we are transforming the active management of
cancer through breakthrough personalized testing. We aim to drive a
new paradigm for cancer management, guiding care from biopsy
through the life of the patient. Our highly sensitive assays
combine tumor-and-normal profiling with proprietary algorithms to
deliver advanced insights even as cancer evolves over time. Our
products are designed to detect minimal residual disease (MRD) and
recurrence at the earliest time points, enable the selection of
targeted therapies based on ultra-comprehensive genomic profiling,
and enhance biomarker strategy for drug development. Personalis is
based in Fremont, California. To learn more, visit
www.personalis.com and connect with us on LinkedIn and X, formerly
known as Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release that are not historical
are “forward-looking statements” within the meaning of U.S.
securities laws, including statements relating to the attributes of
or opportunity for NeXT Personal or the expected benefits of the
expanded relationship with Tempus. Such forward-looking statements
involve known and unknown risks and uncertainties and other factors
that may cause actual results to differ materially from any
anticipated results or expectations expressed or implied by such
statements, including the risks, uncertainties and other factors
that relate to the success of Tempus’ sales and marketing efforts,
including the anticipated acceleration of the market penetration of
NeXT Personal. These and other potential risks and uncertainties
that could cause actual results to differ materially from the
results predicted in these forward-looking statements are described
under the captions “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in
Personalis’ Annual Report on Form 10-K for the year ended December
31, 2023, filed with the Securities and Exchange Commission (SEC)
on February 28, 2024, its Quarterly Report on Form 10-Q for the
quarter ended March 31, 2024, filed with the SEC on May 8, 2024,
its Quarterly Report on Form 10-Q for the quarter ended June 30,
2024, filed with the SEC on August 7, 2024, and its Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024, filed
with the SEC on November 6, 2024. All information provided in this
release is as of the date of this press release, and any
forward-looking statements contained herein are based on
assumptions that we believe to be reasonable as of this date. Undue
reliance should not be placed on the forward-looking statements in
this press release, which are based on information available to us
on the date hereof. Personalis undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241216417697/en/
Investors: Caroline Corner investors@personalis.com
415-202-5678
Media Contact: Patrick Schmidt pr@personalis.com
630-290-2787
Personalis (NASDAQ:PSNL)
過去 株価チャート
から 11 2024 まで 12 2024
Personalis (NASDAQ:PSNL)
過去 株価チャート
から 12 2023 まで 12 2024